Publications
5674 Results
- Journal / Conference
- Nature Communications Sep 19;13(1):5478
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID36117191
- PMC
- PMC9482920
- Study Number(s)
- CTSU/C80405
ARID1A mutations induce an EGFR-like signature and confer intrinsic and acquired resistance to cetuximab treatment in colon cancer
- Journal / Conference
- Bladder Cancer, volume 8; issue 4
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0337
Paper Alert—Implementing a New Standard of Care [Commentary]
- Journal / Conference
- JAMA Network Open Nov 1;5(11):e2241720
- Year
- 2022
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- PMID36367721
- PMC
- PMC9652759
- Study Number(s)
- S1200
Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial
- Journal / Conference
- Journal of the Comprehensive Cancer Network Oct;20(10):1080-1090
- Year
- 2022
- Research Committee(s)
- Cancer Survivorship
- PMID
- PMID36240847
NCCN Guidelines® Insights: Survivorship, Version 1.2022
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9559); American Society of Clinical Oncology
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/EA6134
Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)
- Journal / Conference
- International Kidney Cancer Symposium (November 4-5, 2022, Austin, TX), TIPS, Poster Board F1 Abstract 49
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/A031801
A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)
- Journal / Conference
- JADPRO Jan/Feb, Vol 14, No 1 (JADPRO Live Conference 2022 (October 20 thru 23, 2022, Aurora, CO))
- Year
- 2022
The Expanding Role of the Advanced Practice Provider in National Cancer Institute Sponsored Trials
- Journal / Conference
- Blood. 2022;140 (supplement 1):10009-10010; ASH Annual Meeting (Dec 10-12, 2022, New Orleans, LA)
- Year
- 2022
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0777
Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age
- Journal / Conference
- Journal of the National Cancer Institute Jan 4;113(1):54-63
- Year
- 2021
- Research Committee(s)
- Breast
- PMID
- PMID32239145
- Study Number(s)
- S0221
Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival
- Journal / Conference
- Journal of the National Cancer Institute Feb 1;113(2):192-198. doi: 10.1093/jnci/djaa082
- Year
- 2021
- Research Committee(s)
- Breast
- PMID
- PMID32497219
- PMC
- PMC7850529